Introduction
============

Human organs for transplantation are scarce in Sweden, as in the rest of the world. Alternatives to transplantation are lacking and it is generally only patients with kidney failure who have a reasonable alternative, i.e. dialysis. However, kidney transplantation is the preferred renal replacement therapy (RRT) due to improved quality of life and health-related outcomes compared with dialysis \[[@sfx088-B1], [@sfx088-B2]\]. The shortage of kidneys available for transplantation limits the number of patients who are able to take advantage of this treatment. This is mainly because too few potential donors are identified. Extensive efforts have been made to increase the number of donors, but the shortage remains. It is therefore important to have a clear understanding of the costs and benefits of transplantation to determine whether interventions to increase available kidneys are worth the cost.

Little is known about the cost of kidney transplantation over time \[[@sfx088-B3]\]. Figures frequently quoted in the Swedish debate are that the health care costs for kidney transplantation are ∼ €115 000 over 10 years, while the corresponding cost for dialysis is said to sum to €460 000--800 000. These numbers are of unclear origin; also, they have figured in the debate for a relatively long time and are probably outdated because of improved technological and medical treatment. Chamberlain *et al*. \[[@sfx088-B4]\] estimated the cost for the first 3 years after transplantation in Sweden to be €44 000--68 000. In Belgium, the 1-year post-transplant health care cost including surgery has been estimated at €40 000 \[[@sfx088-B5]\], while the first- and second-year post-transplant costs in Germany have been estimated at €34 000 and €14 000, respectively \[[@sfx088-B6]\]. A French single-centre study estimated the cost of the hospital stay for kidney transplantation to be €14 000 \[[@sfx088-B7]\].

Previous studies are generally descriptive in their costing approach in that no comparisons are made with the expected health care cost in the absence of transplantation. The follow-up time is also limited to 1 year, or at most a few years \[[@sfx088-B4]\]. An exception to this is a UK study that found the total in- and outpatient cost of kidney transplantation, excluding the transplantation surgery, to be €9600 in the first year and decreasing gradually to €2600 in the sixth year after transplantation. Kidney transplantation compared with haemodialysis (HD) was estimated to result in cost savings of ∼75% in the first 4 years post-transplantation \[[@sfx088-B3]\].

The purpose of this study was to estimate the health care costs in Sweden of kidney transplantation and dialysis over 10 years from a health care perspective stratified for gender and age and to estimate the expected cost savings of transplantation. We also investigated which factors are associated with the effectiveness of kidney transplantation. This study contributes to our understanding of longer-term outcomes and costs by using a longer follow-up time and through comparison with a counterfactual situation using the transplanted patients as their own controls in a before--after approach.

Materials and methods
=====================

Patients on RRT were identified through the Swedish Renal Register, which has a coverage of \>95% \[[@sfx088-B8]\] and close to 100% for transplanted patients \[[@sfx088-B9]\]. This register has been linked to data on health care utilization and costs from the Region Skåne and Stockholm County, two of the largest health care administrative areas in Sweden, corresponding to ∼35% of the Swedish population.

Transplanted patients are not representative of all patients on RRT and therefore we could not use patients on dialysis as a control group. Instead, transplanted patients were used as their own controls and a before--after design was employed. The cost of health care utilization in the year before transplantation was assumed to continue in the absence of a transplant. Any cost reduction after transplantation, compared with the year before, was attributed to the kidney transplantation. The validity of this assumption will be discussed based on the development over time of costs for patients on dialysis, which will therefore also be analysed.

Patients who started RRT treatment (dialysis or deceased- or living-donor transplantation) during 1998--2012 were included in the study. Five patients lacking information on current treatment (lost to follow-up) and 15 patients for whom cost information was lacking during the year of transplantation/dialysis were excluded, leaving a sample size of 4680, of whom 1220 received transplantation. Due to missing health care costs, the sample of transplantation patients was reduced to 1081 in the cost analysis.

The total health care cost for the year of the transplantation was calculated. This year was defined to have started 8 days before the date of transplantation to capture the full inpatient episode related to the transplantation. Costs for each year, up to 10 years before and 10 years after the year of transplantation, were calculated for each full year until death or until the end of the study period. For patients who died during the study period, only the last full year was included in the analysis, calculated from the date of transplantation or start of RRT (a sensitivity analysis was performed to calculate the health care cost during the last year of a patient's life based on their date of death). In the analysis, the number of years differed between patients and the sample size was thus reduced with each additional year of follow-up. An alternative approach was also used in which only the costs occurring while on RRT were included. In other words, using left censoring of the costs before transplantation, the 'before' observations were reduced and all patients who initiated RRT with a transplantation were excluded.

Patients on dialysis were treated in the same manner as transplanted patients, but we used two different starting points: start of RRT and an adjusted start of RRT based on the average time patients in the sample had to wait for a transplant (625 days) (for both groups, the starting point was calculated in relation to the start of RRT; the left-censoring approach cannot be used for dialysis). The latter starting point allows the cost of dialysis to change over time in treatment, e.g. through complications, better representing the counterfactual situation for transplanted patients. All costs were adjusted to the price level of 2012 using the Swedish consumer price index.

As well as analyses stratified by gender, age and transplantation type, three subgroup analyses based on graft outcome were performed: (i) functioning graft during follow-up, (ii) return to dialysis during follow-up and (iii) additional transplantation during follow-up. The average health care cost for the transplantation and dialysis episodes was calculated, based on the *International Statistical Classification of Diseases and Related Health Problems, 10th revision* (ICD-10) diagnosis and activity codes KAS10, KAS20, DR014, DR015, DR016, DR017, DR024, Z491 and Z492. The *t*- and *χ*^2^-tests were used to examine differences between groups.

An ordinary least-squares (OLS) regression was run on the cost savings of transplantation during the first year after transplantation. This was done in order to identify factors associated with the effectiveness of transplantation in terms of cost savings.

Stata version 13 (StataCorp, College Station, TX, USA) was used for all statistical analyses. This study was approved by the Lund Regional Ethical Review Board, Lund, Sweden (dnr: 2014/144).

Results
=======

Table [1](#sfx088-T1){ref-type="table"} compares patients included in this study with patients in the rest of Sweden, indicating that the sample is representative for the whole of Sweden. Within-sample comparison shows large differences between transplanted and dialysis patients. This implies, as expected, that these two groups should not be compared directly. Table 1.Comparison between transplanted patients and patients on dialysis in the study sample from Region Skåne and Stockholm County and patients in the rest of SwedenTransplantationDialysisStudy sample (*n* = 1220)Rest of Sweden (*n* = 2855)Study sample (*n* = 3460)Rest of Sweden (*n* = 8684)Women (%)34373534Age at start of RRT (years)45.546.569.269.8[^a^](#tblfn1){ref-type="table-fn"}Start date of RRT (mean)4 February 200516 December 200423 July 200514 June 2005Tx date (mean)16/10/200610/8/2006Number of risk factors1.11.22.12.1Waiting time for Tx (days)627610Patient deceased (%)14158787Treatment at follow-up: HD (%)888180Treatment at follow-up: PD (%)111920Treatment at follow-up: Tx (%)9191Number of Txs1.051.06Total time in HD (days)506465825812Total time in PD (days)248261226231Total time with transplant (days)24502524Total time on RRT (days)3211325810591055[^1]

Health care costs for patients on RRT
-------------------------------------

Figure [1](#sfx088-F1){ref-type="fig"} shows the average health care cost in the year of transplantation (year 0) and the preceding (years −1 to −10) and post-transplantation (years 1--10) periods. Figure [1](#sfx088-F1){ref-type="fig"} shows a rapid rise in cost until year 0. After an initial cost increase of €10 000 at year 0, compared with year −1, the cost fell rapidly in year \>0. The average cost fell by 77% during the first year after transplantation (year +1) (Table [2](#sfx088-T2){ref-type="table"}) and then remained relatively stable, only to start increasing in post-transplantation year 7. We found large cost differences between patients and several genuine outliers increased the average cost. The average cost during year \<0 for transplant patients on RRT (censored) was markedly higher compared with the transplant group in general. However, it did not affect the cost savings of transplantation as the costs converged around year −1. Altogether 173 transplant patients passed away during the follow-up, with an average last life-year health care cost of €83 000 (median €32 000). Table 2.Health care cost savings over 10 years due to kidney transplantationYearObservations (*n*)Cost, (€) (SD)Expected cost in the absence of transplantation (€)[^a^](#tblfn2){ref-type="table-fn"}Cost savings (€)[^b^](#tblfn3){ref-type="table-fn"}Proportion saved (%)[^b^](#tblfn3){ref-type="table-fn"}0108162 551 (73 229)52 476−10 076−19+196011 938 (27 669)52 47640 53777+284711 258 (29 696)52 47641 21879+373811 390 (27 561)52 47641 08578+463811 838 (25 898)52 47640 63877+552812 870 (35 853)52 47639 60675+644512 478 (26 107)52 47639 99776+735713 808 (33 050)52 47638 66774+827714 077 (29 665)52 47638 39873+921216 839 (36 636)52 47635 63668+1013917 834 (30 583)52 47634 64266[^2][^3]

![Health care costs in euros (€) per patient and year for patients on RRT. Year 0 = the year of transplantation or the first year on RRT, plus 625 days for patients on dialysis (625 days corresponds to the average waiting time for a transplant in the sample).](sfx088f1){#sfx088-F1}

The corresponding costs for patients on dialysis are also shown in Figure [1](#sfx088-F1){ref-type="fig"}, where year 0 is the start of RRT, adjusted for average waiting time for a kidney among transplanted patients. One peak can be noted 2 years before the adjusted start of RRT (i.e. at the actual start of RRT), which is probably related to high initial costs due to an acute phase of the disease. The health care cost during the last life year among dialysis patients was estimated at €86 000 (median €81 000), which corresponds to the expected cost of a patient after a few years of dialysis (Figure [1](#sfx088-F1){ref-type="fig"}).

Age, gender and transplantation type stratification
---------------------------------------------------

Comparing younger \[mean age 42 (range 1--57) years\] with older \[mean age 67 (range 58--85) years\] transplanted patients showed significantly higher health care costs for older patients in the year \<0 but not the years 0 or \>0. Transplanted children (\<16 years of age), however, had substantially higher health care costs in the years 0 and \>0 compared with adults. The average costs for year 0 for patients \<16 years of age were €115 000 per patient, which is about twice as high as for adults (only two children \<16 years of age were defined as dialysis patients in the sample, the reason why a cost comparison between children and adults could not be made). For patients on dialysis, significantly higher health care costs were calculated for younger \[mean age 63 (range 0--74) years\] compared with older \[mean age 81 (range 74--97) years\] patients in years \<0, 0 and 1--5 after the start of RRT (Figure [2](#sfx088-F2){ref-type="fig"}). Stratifying for transplantation type \[deceased-donor (57%) or living-donor (43%) transplantation\] showed lower health care costs post-transplantation for living-donor transplantation. However, the difference was only statistically significant for every second year, indicating no trend (data not shown). Gender differences were only found for a few random years before the start of dialysis/transplantation and are therefore not reported further.

![Health care costs in euros (€) for patients on dialysis, stratified by age. Year 0 = the first year on RRT. Younger \[mean age 63 (range 0--74) years\] compared with older \[mean age 81 (range 74--97) years\] patients.](sfx088f2){#sfx088-F2}

Outcome stratification
----------------------

Patients who received an additional transplant during the study period were younger (average 49 years old) compared with other transplant patients (54 years old for successful transplantation and 56 years old for return to dialysis), while the mortality rate was higher among patients who returned to dialysis (29% versus 13% for the other two groups).

The average health care costs for successful transplants (85% of the total number of transplants) had a similar development as with all transplantations, though with a somewhat larger cost savings. Patients who received a second transplant had substantially higher average costs for year ≥0 (Table [3](#sfx088-T3){ref-type="table"}). Transplant patients who returned to dialysis had significantly higher costs for year \<0 and year ≥0 compared with patients who had successful transplantations (Table [3](#sfx088-T3){ref-type="table"}). The costs also increased faster in the years \>0 as more and more patients returned to dialysis. Table 3.Health care costs stratified by outcome, up to 10 years before and after kidney transplantation (Tx)Successful transplantationRetransplantationReturn to dialysisYear[^a^](#tblfn4){ref-type="table-fn"}Observations (*n*)Average cost (€)Observations (*n*)Average cost (€)Observations (*n*)Average cost (€)−1046416447621267021\*\*−95572125102595357398\*\*−86303116121481395699−76983584153729516957\*−677355031985745910 247\*−584279141996397012 640\*−490214 4562712 5828122 800−395422 3793422 5869428 844−299333 9064138 60010143 223\*−1102851 5964347 86910662 868\*092858 0364794 001\*\*10688 135\*\*181484744544 612\*\*10125 299\*\*271064874251 927\*\*9528 931\*\*361172064143 353\*\*8625 878\*\*452173534043 506\*\*7725 730\*\*542761813735 975\*\*6444 139\*\*635164773438 642\*\*6032 759\*\*727971773133 525\*\*4740 166\*\*821165042531 337\*\*4142 529\*\*915883252431 139\*\*3050 238\*\*1010068641740 718\*\*2250 013\*\*[^4]

Health care cost for episodes directly related to dialysis/transplantation
--------------------------------------------------------------------------

The average cost of the inpatient episode when the transplantation was performed was €34 816. This amount does not include costs for identification of a donor and organ donation. The average cost of an outpatient episode of dialysis averaged €486. With an average of three episodes of HD per week, the yearly cost equalled €75 800. This does not include dialysis during inpatient care, as this would overestimate the cost of dialysis since those episodes generally have other primary activities. Some dialysis-related costs exist in primary care, but they are rare and relatively low and were therefore disregarded.

Factors associated with health care cost savings
------------------------------------------------

Table [4](#sfx088-T4){ref-type="table"} shows factors associated with the effectiveness of kidney transplantation, here defined as the cost savings in the health care sector in the first year after transplantation compared with the year before transplantation. Neither gender nor year of transplantation nor waiting time had an influence on the size of the cost savings. Both requiring an additional transplantation and age were associated with higher costs and therefore with reduced cost savings. However, the age effect was isolated to the younger part (mean split) of the sample, where each additional year of age was estimated to reduce the cost savings by €1084. The overall explanatory power of the model is very low. Table 4.Regression results for before--after differences in health care costs in euros (€)Full sample\< 49 years\> 49 yearsWomen−5120−5296−6082Year of transplantation509−8241137Age at transplantation445\*\*1084\*\*\*912Return to dialysis16 548\*547821,397Retransplantation52 708\*\*\*57 462\*\*\*41 241\*Waiting time−3−19\*\*\*6Constant−73 814−72 703\*\*\*−115 890\*\*\**N*816351465Adjusted *R*^2^0.0200.1120.007[^5]

Discussion
==========

Using a before--after design, we found that kidney transplantation rapidly reduced the health care cost per patient. Although the results indicate that the cost savings was reduced over time, the cost was still 75% lower than the expected cost in the absence of transplantation after 6 years and 66% lower after 10 years. This corresponds to a total cost savings of €380 000 (€324 000 discounted) over 10 years for each transplanted patient. The health care costs for dialysis showed an upward trend over time in treatment. This indicates that the assumption that the cost during the year before transplantation would continue in the absence of transplantation is conservative and that the actual cost savings of a kidney transplantation is probably higher. Li *et al.* \[[@sfx088-B3]\] found in the UK that health care costs for patients on dialysis and transplantation actually fell over time in treatment, as did the probability of incurring costs. However, the cost development of dialysis reported in Li *et al.* is not an appropriate estimation of the health care costs in the absence of a transplant, as the cost of dialysis maintenance was excluded \[[@sfx088-B3]\]. Therefore theirs are not comparable with the figures reported in the current study.

The size of the cost savings depends on the outcome of the transplantation, where successful transplantations have the largest cost savings. For patients who receive an additional transplant during the follow-up, the first transplantation is only cost saving after 9 years. This is related to the high cost during the year of and the years after the first transplantation. However, even for patients who return to dialysis, kidney transplantation is cost saving already in the first year after transplantation and remains so for the full 10-year follow-up period. This is so despite a much higher cost for the year of transplantation compared with successful transplantations. It is interesting to note that patients in our study who returned to dialysis after transplantation had significantly higher health care costs for almost all 10 years prior to the transplantation. The year of transplantation was not associated with the size of the estimated cost savings, indicating that the study period is homogeneous and appropriate for pooling.

No particular differences in health care costs could be found between men and women and between younger and older patients, which generally is in line with the findings reported in Li *et al.* \[[@sfx088-B3]\]. There were two exceptions to this: children (\<16 years of age) undergoing a kidney transplant had substantially higher costs compared with adults despite a higher rate of living-donor transplantation (79%) and younger patients on dialysis had higher costs compared with older patients. The latter could potentially be explained by the fact that diabetic nephropathy is more common as primary kidney disease among younger patients. It should be noted that only one patient among the younger part of the sample, and none of the children, underwent pancreas transplantation.

The results were confirmed in the OLS regression, where age at transplantation was only significant for the younger part of the sample. Neither gender nor waiting time was significantly associated with cost savings. Indications are that, compared with living-donor transplantation, deceased-donor transplantation is associated with higher costs post-transplantation. This would be expected based on prior research showing better outcomes after living-donor transplantation. However, the difference during follow-up was borderline significant as often as it was borderline insignificant, making it difficult to draw any conclusions. Further studies are therefore needed to establish whether other factors are associated with both transplantation type and health care costs post-transplantation.

Chamberlain *et al.* \[[@sfx088-B4]\] estimated the cost for the first 3 years after transplantation in Sweden to be €45 500--70 500. These figures cannot be directly compared with the results of the current study due to differences in definitions. However, an attempt to adjust our results to achieve greater harmonization with Chamberlain *et al.*, where the cost of the actual transplantation episode was subtracted, would give a 3-year cost of €51 000 in the present study. This is at the lower end of the range estimated in Chamberlain *et al.*, lending some credibility to both figures. Chamberlain *et al.* \[[@sfx088-B4]\] found, when comparing their figures to other European countries, that the Swedish costs were about twice as high, which would indicate that the estimated costs in this study are not generalizable to other countries. However, the estimated cost savings are similar to prior studies. Reporting from the UK, Li *et al.* \[[@sfx088-B3]\] found similar cost savings after 6 years as reported in the current study and a likewise rapid decrease in health care costs after kidney transplantation has previously been shown in Finland \[[@sfx088-B10]\].

In this study, we calculated the average health care costs for each full year after transplantation or start of RRT. This approach runs the risk of excluding some costs related to a patient's death. We therefore also calculated the cost of the last life year for all patients who died during the study period. These costs (∼ €85 000) were relatively similar between transplanted patients and patients on dialysis, which implies that the cost increase related to death is higher among transplanted patients. However, this larger cost increase among transplanted patients does not affect the cost-saving feature of transplantation.

Limitations
-----------

The assumption that the costs for the year before transplantation will continue in a scenario without transplantation is conservative, as the cost of dialysis tends to increase over time in treatment. A reduced mortality rate for transplantation compared with dialysis can be expected to continue for up to 25 years after treatment \[[@sfx088-B11]\]. The current study's follow-up period of 10 years can therefore be seen as a conservative limitation probably underestimating the effect of transplantation compared with dialysis. However, prolonged life also implies health care costs during the additional life years. Another conservative limitation is that 8 days before the transplantation was defined as the start of the transplantation year. This may have overestimated the health care costs, as some costs due to the underlying disease will be attributed to the transplantation year.

One data limitation is the exclusion of private health care providers in one of the two regions under study, Skåne, due to legal restrictions. Analysis of the data from the other region, Stockholm, where both public and private providers were included, shows that this limitation underestimates the costs. However, the underestimation is relatively small and the cost structures of private and public care are similar, indicating that the effect on the analysis and conclusions should be minor.

Finally, the current study does not include all costs related to kidney transplantation. Costs related to identification and care of a presumptive donor and graft retrieval should be included in the total health care costs.

Future research should apply more advanced statistical methods in order to estimate the cost savings of switching a patient on dialysis to transplantation. Together with other future studies on the treatment effects on health and socioeconomic outcomes, this would allow for much needed cost-effectiveness estimates of interventions and would ultimately be hoped to increase donations.

Conclusion
==========

This study shows that performed kidney transplantations have resulted in substantial cost savings for the Swedish health care system over 10 years following transplantation. An expansion of the research that carefully identifies patients on dialysis with the highest ability to benefit from transplantation is well placed to further reduce the health care costs of RRT. It is hoped that positive medical values along with cost savings in the health care sector may lead to increased engagement for organ donation in intensive care and consequently to more candidates for organ donation being identified.
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[^1]: Statistically significant differences between patients in the sample and patients in the rest of Sweden, at the 5% significance level. HD, haemodialysis; PD, peritoneal dialysis; Tx, transplantation.

[^2]: Expected cost corresponds to health care cost the year before transplantation \[standard deviation (SD) = €53 407\].

[^3]: Note that a negative value means a higher cost compared with the expected cost.

[^4]: Year 0 = the year of transplantation. Asterisks indicate significant differences compared with successful transplantation at the \*\*1% and \*5% significance level.

[^5]: OLS regressions with statistical significance at the \*\*\*1%, \*\*5% and \*10% significance level, respectively. A negative figure indicates increased cost savings.
